<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9068">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02988882</url>
  </required_header>
  <id_info>
    <org_study_id>OTX-15-002</org_study_id>
    <nct_id>NCT02988882</nct_id>
  </id_info>
  <brief_title>Study Evaluating the Efficacy and Safety of OTX-DP for the Treatment of Chronic Allergic Conjunctivitis Using a Modified Conjunctival Allergen Challenge Model (CAC®)</brief_title>
  <official_title>A Multi-Center, Randomized, Double-Masked, Vehicle Controlled Phase 3 Study Evaluating the Efficacy and Safety of OTX-DP for the Treatment of Chronic Allergic Conjunctivitis Using a Modified Conjunctival Allergen Challenge Model (CAC®)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ocular Therapeutix, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ORA, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ocular Therapeutix, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of OTX-DP compared to
      Placebo Drug Delivery Vehicle (PV) for the treatment of the signs and symptoms of chronic
      allergic conjunctivitis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ocular Itching</measure>
    <time_frame>Day 8</time_frame>
    <description>Ora Calibra Conjunctival Allergen Challenge Ocular Itching Scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Conjunctival Redness</measure>
    <time_frame>Day 15</time_frame>
    <description>Ora Calibra Ocular Hyperemia Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Conjunctival Redness</measure>
    <time_frame>27-30 Days post insertion</time_frame>
    <description>Ora Calibra Ocular Hyperemia Scale</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">86</enrollment>
  <condition>Chronic Allergic Conjunctivitis</condition>
  <arm_group>
    <arm_group_label>OTX-DP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>OTX-PV</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OTX-DP (Dexamethasone)</intervention_name>
    <description>OTX-DP contains 0.4 mg dexamethasone and is designed to provide a sustained and tapered release of therapeutic levels of dexamethasone to the ocular surface for approximately 30 days.</description>
    <arm_group_label>OTX-DP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo - PV</intervention_name>
    <description>The control test article, PV, is the same fluorescent PEG hydrogel punctum plug as OTX-DP, except that it does not contain drug</description>
    <arm_group_label>OTX-PV</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. be at least 18 years of age of either sex and any race;

          2. provide written informed consent and sign the HIPAA form;

          3. be willing and able to follow all instructions and attend all study visits;

          4. (for females capable of becoming pregnant) agree to have urine pregnancy testing
             performed at screening (must be negative) and at exit visit ; must not be lactating;
             and must agree to use a medically acceptable form of birth control throughout the
             study duration and for at least 14 days prior to insertion of the investigational
             product (Visit 3b) and for one month after investigational product removal. Women
             considered capable of becoming pregnant include all females who have experienced
             menarche and have not experienced menopause (as defined by amenorrhea for greater
             than 12 consecutive months) or have not undergone successful surgical sterilization
             (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy);

          5. have a positive history of ocular allergies and a positive skin test reaction to a
             perennial allergen (cat dander, dog dander, dust mites, cockroaches) and a seasonal
             allergen (trees, grasses, and/or ragweed) as confirmed by the allergic skin test
             given at the subject's Screening visit;

          6. have a calculated visual acuity of 0.7 logMAR or better in each eye as measured using
             an ETDRS chart;

          7. have a positive bilateral CAC® reaction to a perennial allergen within 10 (±2)
             minutes of instillation of the last titration of allergen at Visit 1;

          8. have a positive bilateral CAC® reaction3 for at least two out of the three time
             points following challenge at Visit 2a and 2b;

          9. have an average of ≥ 3 itching and ≥2.5 conjunctival redness for both eyes after
             post-CAC® assessments at Visit 3a;

         10. be able and willing to avoid all disallowed medication for the appropriate washout
             period and during the study (see exclusion 6);

         11. be able and willing to discontinue wearing contact lenses for at least 72 hours prior
             to and during the study trial period.

        Exclusion Criteria:

          1. have known contraindications or sensitivities to the use of any of the
             investigational product medication or components;

          2. have any ocular condition that, in the opinion of the investigator, could affect the
             subject's safety or trial parameters (including but not limited to narrow angle
             glaucoma, clinically significant blepharitis, follicular conjunctivitis, iritis,
             pterygium or a diagnosis of dry eye);

          3. have had a history of refractive surgery (including LASIK procedures) within the past
             2 years;

          4. have a known history of retinal detachment, diabetic retinopathy, or active retinal
             disease;

          5. have the presence of an active ocular infection (bacterial, viral or fungal), or
             positive history of an ocular herpetic infection at any visit;

          6. use any of the following disallowed medications* during the period indicated prior to
             Visit 1 and during the study: 7 Days

               -  systemic or ocular H1 antihistamine, H1 antihistamine/mast-cell stabilizer drug
                  combinations, H1 antihistamine- vasoconstrictor drug combinations;

               -  decongestants;

               -  monoamine oxidase inhibitors;

               -  all other topical ophthalmic preparations (including artificial tears);

               -  lid scrubs;

               -  prostaglandins or prostaglandin derivatives;

               -  ocular, topical, or systemic nonsteroidal anti-inflammatory drugs (NSAIDs); 14
                  Days

               -  inhaled, ocular or topical corticosteroids or mast cell stabilizers; 45 Days

               -  depot-corticosteroids; *Note: Currently marketed over-the-counter anti-allergy
                  eye drops (ie anti-histamine/ vasoconstrictor combination products such as
                  Visine®-A®) may be administered to subjects at the end of the subject's last
                  visit, after all evaluations are completed;

          7. have a congenital or ocular anomaly (including punctal or lid ectropion, entropion,
             trichiasis, or supernumerary puncta) or anomalies of the punctum (including lack of
             good punctal apposition in both eyes);

          8. have a current diagnosis or history of Herpes Simplex Keratitis;

          9. have a diagnosis of any significant illness [eg, an autoimmune disease, severe
             cardiovascular disease (including arrhythmias), or condition requiring
             immunosuppressives or cancer chemotherapeutic agents]. This includes but is not
             limited to: alcohol or drug abuse, hypertension, diabetes, rheumatoid arthritis,
             lupus, thyroid disease, Parkinson's disease, hepatitis, scleroderma, vitamin a
             deficiency, Sjögren's syndrome, a history of status asthmaticus, a known history of
             persistent moderate or severe asthma, or a known history of moderate to severe
             allergic asthmatic reactions to any of the study allergens;

         10. have a score of &gt;0 for itching and/or &gt;1 for conjunctival redness prior to challenge
             (at Visit 1) in either eye;

         11. have planned surgery (ocular or systemic) during the trial period or within 30 days
             after;

         12. have used an investigational drug or medical device within 30 days of the study or be
             concurrently enrolled in another investigational product trial;

         13. be a female who is currently pregnant, planning a pregnancy, lactating, not using a
             medically acceptable form of birth control throughout the study duration and for at
             least 14 days prior to insertion of the investigational product and for one month
             after investigational product removal, or has a positive urine pregnancy test at
             Visit 1;

         14. have an intraocular pressure that is less than 5 mmHg or greater than 22 mmHg or any
             type of glaucoma at Visit 1;

         15. have had a history of an IOP increase as a result of steroid treatment.

         16. Punctum size is smaller than 0.4 mm or greater than or equal to 1.0 mm;

         17. Punctum is too small to allow transient dilation to 0.7 mm prior to insertion of
             OTX-DP or the PV.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>December 2016</verification_date>
  <lastchanged_date>December 7, 2016</lastchanged_date>
  <firstreceived_date>December 2, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Conjunctivitis</mesh_term>
    <mesh_term>Conjunctivitis, Allergic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone 21-phosphate</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
